RESUMO
An area of current research in Alzheimer's disease (AD) is the biosynthetic pathway of amyloid beta peptides (Abeta) via consecutive proteolytic cleavages of the amyloid beta precursor protein (APP) by BACE and gamma-secretase enzymes. APP is first cleaved by BACE to form a C-terminal fragment APP-betaCTF, or also called C99, which then undergoes further cleavage by gamma-secretase to form Abeta. Inhibitors of gamma-secretase have been observed to yield a so-called 'Abeta rise' phenomenon whereby low inhibitor concentrations result in an increase in Abeta levels while high inhibitor concentrations result in lower Abeta levels. A previous report from our labs indicated that this phenomenon was related to ratios of APP-betaCTF substrate relative to gamma-secretase enzyme. A quantitative Western blot analysis was used with a recombinant C100 protein as calibration standards to assess the relationship of APP-betaCTF, gamma-secretase enzyme and various inhibitors resulting in the 'Abeta rise'. An on-line liquid chromatography mass spectrometry (LC-MS) method employing the 'surrogate peptide' methodology was developed to accurately quantify the recombinant C100 used in the Western blot analyses. The surrogate peptide approach utilizes tryptic digestion of the protein to stoichiometrically yield a unique peptide fragment, in this case (C100)Abeta17-28 (LVFFAEDVGSNK) that can be readily detected by LC-MS. The absolute quantitative assessment of C100 was accomplished using synthetic Abeta17-28 to generate calibration curves over a 0.001-1 microM range and 15N isotopically labeled Abeta1-40 as the internal standard for enzymatic digestion and its proteolytic peptide [15N]-Abeta17-28 for the analysis.